Iowa has recently joined 27 other states that have passed biosimilars legislation. On behalf of the 619,000 adults (plus 2,800 children) in Iowa with doctor-diagnosed arthritis, we’d like to thank Governor Branstad for signing House File 305 into law on Friday, March 10, 2017.
The bill allows Iowa pharmacists the ability to dispense safe and potentially less expensive biologic medications to patients, by substituting an FDA approved interchangeable biosimilar for a prescribed biologic product. The law also requires that the prescriber and patient be notified when there is a substitution. Continue reading Victory in Iowa: Biosimilar Legislation Signed Into Law!→
A record number of individuals have achieved the Arthritis Foundation’s highest advocacy honor in 2016 and became Platinum Ambassadors. At the 2017 Advocacy Summit, March 6-7, in Washington, DC, 41 new Platinum Ambassadors will be recognized for their outstanding advocacy accomplishments on behalf of the arthritis community.
Platinum Ambassadors are an elite group of Advocates who go above and beyond the call of duty by accomplishing a challenging list of advocacy assignments along with four bonus activities, all while raising funds to support the Foundation’s mission to conquer and cure arthritis.
For years now, many arthritis patients have utilized biologic medications to great effect. Biologics have allowed those with arthritis, as well as many other chronic diseases, to stabilize their condition and help them better quality lives. Now, due to innovation, new medications are coming to market which could provide arthritis patients with more, and potentially less expensive, options. These new medications are called “biosimilar” medications which are similar to, but not exact copies of name brand biologics. Continue reading Victory in Montana! Governor Bullock Signs Biosimilar Substitution→
As we ring in the new year, we celebrate a major step therapy legislative win in New York! An increasing number of health insurers around the country are utilizing fail first or step therapy practices that require patients to try and fail one or more formulary medications before providing coverage for the originally prescribed non-formulary medication. Rather than taking into account the needs of the individual patient, insurers are determining drug sequences based on cost. These practices can vary wildly insurer to insurer with no consistency on how to establish or apply these fail first protocols. Continue reading New York Step Therapy Reform Legislation Signed into Law by Governor Cuomo→